MedPath

Ketoconazole

Generic Name
Ketoconazole
Brand Names
Extina, Ketodan, Ketoderm, Nizoral, Xolegel, Ketoconazole HRA
Drug Type
Small Molecule
Chemical Formula
C26H28Cl2N4O4
CAS Number
65277-42-1
Unique Ingredient Identifier
R9400W927I
Background

Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections. It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus. Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981. At this time it was considered a significant improvement over previous antifungals, miconazole and clotrimazole, due to its broad spectrum and good absorption. However, it was discovered that ketoconazole produces frequent gastrointestinal side effects and dose-related hepatitis. These effects combined with waning efficacy led to its eventual replacement by triazole agents, fluconazole, itraconazole, voriconazole, and posaconazole. Ketoconazole and its predecessor clotrimazole continue to be used in topical formulations.

Indication

Ketoconazole is used in the treatment or prevention of fungal infections including blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. In Europe, it is also used in the treatment of endogenous Cushing's syndrome.

Associated Conditions
Bacterial Vaginosis (BV), Blastomycosis, Candidiasis, Systemic, Chromoblastomycosis, Chronic Mucocutaneous Candidiasis (CMC), Coccidioidomycosis, Dandruff, Endogenous Cushing's Syndrome, Fungal Infections, Histoplasmosis, Paracoccidioidomycosis, Seborrheic Dermatitis, Tinea Corporis caused by Epidermophyton floccosumin, Tinea Corporis caused by Trichophyton mentagrophytes, Tinea Corporis caused by Trichophyton rubrum, Tinea Cruris caused by Epidermophyton floccosumin, Tinea Cruris caused by Trichophyton mentagrophytes, Tinea Cruris caused by Trichophyton rubrum, Tinea Pedis caused by Epidermophyton floccosumin, Tinea Pedis caused by Trichophyton mentagrophytes, Tinea Pedis caused by Trichophyton rubrum, Vaginal Candidiasis, Vulvovaginal Candidiasis, Cutaneous candidiasis, Recalcitrant Dermatophytosis, Tinea versicolor caused by Malassezia infection
Associated Therapies
-

A Comparison of Fluconazole and Ketoconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems

Not Applicable
Completed
Conditions
Candidiasis, Esophageal
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Pfizer
Registration Number
NCT00002304
Locations
🇺🇸

Eisenhower Med Ctr, Rancho Mirage, California, United States

🇺🇸

Univ Hosp, Boston, Massachusetts, United States

🇺🇸

Buckley Braffman Stern Med Associates, Philadelphia, Pennsylvania, United States

and more 39 locations

Acute Respiratory Distress Syndrome Clinical Network (ARDSNet)

Phase 3
Completed
Conditions
Respiratory Distress Syndrome, Adult
Lung Diseases
First Posted Date
1999-10-28
Last Posted Date
2016-03-23
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Registration Number
NCT00000579
Locations
🇺🇸

Baystate Medical Center, Springfield, Massachusetts, United States

🇺🇸

Duke University, Durham, North Carolina, United States

🇺🇸

Wake Forest University, Winston-Salem, North Carolina, United States

and more 18 locations
© Copyright 2025. All Rights Reserved by MedPath